Si R. Sun
238 Ziyang Road
Wuhan, 430060, China
Wuhan, 430060, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications
Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 11, 2026
Genetic hearing loss GJB2 c.109G>A (p.Val37Ile) consultation key points and clinical significance
Journal: Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
Published: April 09, 2026
EZH2 inhibition overcomes immune evasion in lung adenocarcinoma by restoring CCL5-mediated T-cell recruitment and MHC class I antigen presentation.
Journal: Acta biochimica et biophysica Sinica
Published: March 03, 2026
A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma.
Journal: NPJ precision oncology
Published: October 15, 2025
DDX41 facilitates PD-L1-mediated immune escape in OSCC via the phase separation and activation STING pathway.
Journal: NPJ precision oncology
Published: August 04, 2025
Understanding Artificial Intelligence in Dental Nursing: An Online Survey on Familiarity, Attitudes, and Expectations.
Journal: The Journal of craniofacial surgery
Published: June 30, 2025
Molecular logic gates based on programmable self-assembly of DNA origami triangles for the detection of nucleic acid molecules.
Journal: Scientific reports
Published: June 10, 2025
Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers.
Journal: Translational lung cancer research
Published: May 08, 2025
Small extracellular vesicle miRNAs as biomarkers for predicting antitumor efficacy in lung adenocarcinoma treated with chemotherapy and checkpoint blockade.
Journal: Frontiers in immunology
Published: February 08, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: November 11, 2024
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation.
Journal: Cell reports. Medicine
Published: October 09, 2024
Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two-cohort, phase 2 trial.
Journal: International journal of cancer
Published: June 18, 2024
Last Updated: 09/26/2026